Wall Street analysts rolled out fresh coverage on five companies Monday, and the theme of the day was decidedly optimistic. Here's what the street's research desks are saying about these newly covered names.
BTIG analyst Thomas Shrader launched coverage on Alto Neuroscience, Inc. (ANRO) with a Buy rating and a $27 price target. That's notable upside from Friday's closing price of $12.11, suggesting Shrader sees substantial potential in the neuroscience company's prospects.
Over in medical technology, B of A Securities analyst Travis Steed initiated coverage on Masimo Corporation (MASI) with a Neutral rating and $162 price target. Masimo finished Friday's session at $151.12, putting the target roughly 7% above current levels. The Neutral stance suggests the analyst sees fair value around these levels.
Leerink Partners analyst Marc Goodman started coverage on Ovid Therapeutics Inc. (OVID) with an Outperform rating and $5 price target. The biotech company closed Friday at $1.3050, making that price target particularly eye-catching—it implies nearly 300% upside if Goodman's thesis plays out.
HC Wainwright & Co. analyst Yi Chen initiated Vivos Therapeutics, Inc. (VVOS) with a Buy rating and $7 price target. Vivos closed Friday at $2.34, so that target represents a potential triple from current levels. Chen clearly sees meaningful value in the therapeutic company's pipeline or business model.
Finally, Benchmark initiated coverage on TAT Technologies Ltd. (TATT) with a Buy rating and $53 price target. The aerospace and defense company finished Friday at $40.04, putting Benchmark's target about 32% above the current price. It's the only non-healthcare name in today's initiation roundup.
The batch of initiations reflects renewed analyst interest in smaller healthcare and specialty industrial names, with most of the calls skewing bullish. Four of the five coverage starts came with Buy or Outperform ratings, suggesting analysts see opportunities in these lesser-followed stocks.
